XmAb13676
EnteredPhase1clinicaltrialinnon-Hodgkinlymphomain2017.
XmAb13676isatumor-targetedantibodythatcontainsbothaCD20bindingdomainandacytotoxicT-cellbindingdomain(CD3).AnXmAbBispecificFcdomainservesasthescaffoldforthesetwoantigenbindingdomainsandconferslongcirculatinghalf-life,stABIlityandeaseofmanufactureonXmAb13676.CD20ishighlyexpressedonB-celltumorcells,includingchroniclymphocyticleukemia(CLL)andnon-Hodgkinlymphoma(NHL)cells.EngagementofCD3byXmAb13676activatesTcellsforhighlypotentandtargetedkillingofCD20-expressingtumorcells.
ThestructuralstabilityandmodularityenabledbytheXmAbBispecificFcdomainallowedthetuningofXmAb13676’spotencytobalanceanti-tumoractivitywiththereductionofimmunetoxicitythatcanresultfromT-cellactivation.